FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323348059> ?p ?o ?g. }

• W4323348059 endingPage "9400" @default.
• W4323348059 startingPage "9392" @default.
• W4323348059 abstract "Abstract The rechallenge strategy is based on the concept that a subset of patients with RAS wild‐type (WT) metastatic colorectal cancer (mCRC) could still benefit of epidermal growth factor receptor (EGFR) inhibition, after progression to an anti‐EGFR based‐therapy. We performed a pooled analysis of two‐phase II prospective trials to determine the role of rechallenge in third‐line mCRC patients with RAS/BRAF WT baseline circulating tumor DNA (ctDNA). Individual data of 33 and 13 patients from CAVE and CRICKET trials that received as third‐line therapy cetuximab rechallenge were collected. Overall survival (OS), Progression‐free survival (PFS), Overall response rate (ORR), Stable disease (SD) >6 months were calculated. Adverse events were reported. For the whole 46 patient population, median PFS (mPFS) was 3.9 months (95% Confidence Interval, CI 3.0–4.9) with median OS (mOS) of 16.9 months (95% CI 11.7–22.1). For CRICKET patients, mPFS was 3.9 months (95% CI 1.7–6.2); mOS was 13.1 months (95% CI 7.3–18.9) with OS rates at 12, 18, and 24 months of 62%, 23%, and 0%, respectively. For CAVE patients, mPFS was 4.1 months (95% CI 3.0–5.2); mOS was 18.6 months (95% CI 11.7–25.4) with OS rates at 12, 18, 24 months of 61%, 52%, 21%, respectively. Skin rash was more frequently reported in CAVE trial (87.9% vs. 30.8%; p = 0.001), whereas a increased incidence of hematological toxicities was observed in CRICKET trial (53.8%% vs. 12.1%; p = 0.003). Third‐line cetuximab rechallenge in combination with either irinotecan or avelumab in RAS/BRAF WT ctDNA mCRC patients represents a promising therapy." @default.
• W4323348059 created "2023-03-08" @default.
• W4323348059 creator A5001689204 @default.
• W4323348059 creator A5003014678 @default.
• W4323348059 creator A5004016643 @default.
• W4323348059 creator A5020655022 @default.
• W4323348059 creator A5030848899 @default.
• W4323348059 creator A5037047992 @default.
• W4323348059 creator A5046559582 @default.
• W4323348059 creator A5047539709 @default.
• W4323348059 creator A5049629149 @default.
• W4323348059 creator A5051613962 @default.
• W4323348059 creator A5056034569 @default.
• W4323348059 creator A5058514609 @default.
• W4323348059 creator A5072503801 @default.
• W4323348059 creator A5074105754 @default.
• W4323348059 creator A5076690603 @default.
• W4323348059 creator A5079437223 @default.
• W4323348059 creator A5080776095 @default.
• W4323348059 creator A5081985776 @default.
• W4323348059 creator A5085124809 @default.
• W4323348059 creator A5088304855 @default.
• W4323348059 creator A5090671983 @default.
• W4323348059 creator A5091765229 @default.
• W4323348059 date "2023-03-07" @default.
• W4323348059 modified "2023-10-18" @default.
• W4323348059 title "Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma <i>RAS/BRAF</i> wild‐type circulating tumor <scp>DNA</scp> : Individual patient data pooled analysis of <scp>CRICKET</scp> and <scp>CAVE</scp> trials" @default.
• W4323348059 cites W2142564546 @default.
• W4323348059 cites W2147834058 @default.
• W4323348059 cites W2156834559 @default.
• W4323348059 cites W242040007 @default.
• W4323348059 cites W2901178367 @default.
• W4323348059 cites W2901367407 @default.
• W4323348059 cites W2907303978 @default.
• W4323348059 cites W2999771324 @default.
• W4323348059 cites W3015725420 @default.
• W4323348059 cites W3027075219 @default.
• W4323348059 cites W3082640385 @default.
• W4323348059 cites W3085126468 @default.
• W4323348059 cites W3123738613 @default.
• W4323348059 cites W3153189337 @default.
• W4323348059 cites W3166456074 @default.
• W4323348059 cites W3191292273 @default.
• W4323348059 cites W3213690829 @default.
• W4323348059 cites W4205227337 @default.
• W4323348059 cites W4224880107 @default.
• W4323348059 cites W4283587297 @default.
• W4323348059 cites W4286296019 @default.
• W4323348059 cites W4289261231 @default.
• W4323348059 cites W4296046852 @default.
• W4323348059 cites W4307401860 @default.
• W4323348059 cites W4308685398 @default.
• W4323348059 cites W4323348059 @default.
• W4323348059 doi "https://doi.org/10.1002/cam4.5699" @default.
• W4323348059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36880426" @default.
• W4323348059 hasPublicationYear "2023" @default.
• W4323348059 type Work @default.
• W4323348059 citedByCount "1" @default.
• W4323348059 countsByYear W43233480592023 @default.
• W4323348059 crossrefType "journal-article" @default.
• W4323348059 hasAuthorship W4323348059A5001689204 @default.
• W4323348059 hasAuthorship W4323348059A5003014678 @default.
• W4323348059 hasAuthorship W4323348059A5004016643 @default.
• W4323348059 hasAuthorship W4323348059A5020655022 @default.
• W4323348059 hasAuthorship W4323348059A5030848899 @default.
• W4323348059 hasAuthorship W4323348059A5037047992 @default.
• W4323348059 hasAuthorship W4323348059A5046559582 @default.
• W4323348059 hasAuthorship W4323348059A5047539709 @default.
• W4323348059 hasAuthorship W4323348059A5049629149 @default.
• W4323348059 hasAuthorship W4323348059A5051613962 @default.
• W4323348059 hasAuthorship W4323348059A5056034569 @default.
• W4323348059 hasAuthorship W4323348059A5058514609 @default.
• W4323348059 hasAuthorship W4323348059A5072503801 @default.
• W4323348059 hasAuthorship W4323348059A5074105754 @default.
• W4323348059 hasAuthorship W4323348059A5076690603 @default.
• W4323348059 hasAuthorship W4323348059A5079437223 @default.
• W4323348059 hasAuthorship W4323348059A5080776095 @default.
• W4323348059 hasAuthorship W4323348059A5081985776 @default.
• W4323348059 hasAuthorship W4323348059A5085124809 @default.
• W4323348059 hasAuthorship W4323348059A5088304855 @default.
• W4323348059 hasAuthorship W4323348059A5090671983 @default.
• W4323348059 hasAuthorship W4323348059A5091765229 @default.
• W4323348059 hasBestOaLocation W43233480591 @default.
• W4323348059 hasConcept C121608353 @default.
• W4323348059 hasConcept C126322002 @default.
• W4323348059 hasConcept C143998085 @default.
• W4323348059 hasConcept C207103383 @default.
• W4323348059 hasConcept C2776694085 @default.
• W4323348059 hasConcept C2778332735 @default.
• W4323348059 hasConcept C2778570526 @default.
• W4323348059 hasConcept C2779998722 @default.
• W4323348059 hasConcept C2780259306 @default.
• W4323348059 hasConcept C2780739268 @default.
• W4323348059 hasConcept C2781187634 @default.
• W4323348059 hasConcept C2908647359 @default.
• W4323348059 hasConcept C44249647 @default.
• W4323348059 hasConcept C526805850 @default.
• W4323348059 hasConcept C71924100 @default.

• next